MDSPhase 1/2NCT01261312
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
A Phase 1/2 study testing Guadecitabine in people with MDS and CMML, run by Astex Pharmaceuticals, Inc. at 16 sites in 2 countries.
Trial summary
Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML… Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- Guadecitabine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 414 participants
- Where
- 16 sitesin 2 countries
- Study dates
- 4 Jan 2011to 22 Jul 2016
- Phase
- Phase 1/2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men or women, 18 years of age or older, with a confirmed diagnosis of international prognostic scoring system (IPSS) intermediate-1, intermediate-2 or high-risk MDS including Chronic Myelomonocytic Leukemia (CMML) or AML.
- In the Dose Escalation Segment, participants who are refractory, relapsed, or unresponsive to standard treatment.
- In the Dose Expansion Segment, hypomethylating agent (HMA) treatment-naïve MDS participants (including CMML), and intermediate-2 or high-risk MDS participant (including CMML) relapsed or refractory to prior HMA treatment are allowed, and treatment-naïve AML participants who is at least 65 years of age will be allowed if they also have at least one of the following criteria
- AML secondary to MDS, chemotherapy, or radiation therapy
- poor cytogenetics
- pre-existing clinically significant dysfunction of the heart or Chronic Obstructive Pulmonary Disease (COPD)
Show all 13Show fewer
- poor performance status, Eastern Cooperative Oncology Group (ECOG), of 2
- Eastern ECOG performance status of 0 to 2.
- Adequate organ function.
- Prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be ≥ 2 weeks off immunosuppressive therapy.
- No major surgery within 4 weeks of first dose of SGI-110.
- No chemotherapy within 2 weeks of first dose of SGI-110 (minimum of 6 weeks for nitrosoureas and 8 weeks for bone marrow transplantation) with the exception of hydroxyurea which will be allowed during course 1 of treatment.
- Sign an approved informed consent form for this study.
Who cannot join
- In the Dose Expansion Segment, which includes the 10-day regimen, participants who have received 2 complete full dose cycles or more of a hypomethylating agent (HMA) decitabine or azacitidine (except for intermediate-2 or high-risk MDS participant (including CMML) relapsed or refractory to prior HMA treatment).
- Acute promyelocytic leukemia (M3 classification).
- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the participant has been disease free for at least 3 years.
- Life-threatening illnesses other than AML or MDS, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the participant's safety, or put the study outcomes at risk.
- Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
- Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.
- With the exception of treatment-naïve elderly AML participants, participants with uncontrolled congestive heart failure (CHF), coronary heart disease (CAD), chronic obstructive pulmonary disease (COPD), or left ventricular ejection fraction (LVEF) of ≤ 50% are excluded, symptomatic or uncontrolled arrhythmias or on continuous corticosteroids.
Trial locations and contacts
16 sites in 2 countries.
16 sites in 2 countries
United States15 sites
Roswell Park Cancer Institute
Buffalo, New York, 14263
University of Chicago Cancer Center
Chicago, Illinois, 60637
Ohio State University
Columbus, Ohio, 43210
Duke University
Durham, North Carolina, 27705
Florida Cancer Specialists - South
Fort Myers, Florida, 33916
MD Anderson Cancer Center
Houston, Texas, 77030
University of Southern California
Los Angeles, California, 90033
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
Tennessee Oncology
Nashville, Tennessee, 37203
Yale University
New Haven, Connecticut, 06520
Cornell University
New York, New York, 10021
Columbia University Medical Center
New York, New York, 10032
Temple University
Philadelphia, Pennsylvania, 19111
Mayo Clinic
Scottsdale, Arizona, 85259
Florida Cancer Specialists - North
St. Petersburg, Florida, 33705
About this study
Official title: A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML participants while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD) as defined in the Dose Escalation Segment.
Read the detailed description
Once the biologically effective dose (BED) and maximum tolerated dose (MTD) is determined in the Dose Escalation Segment, the Dose Expansion Segment will randomize participants with MDS, treatment naïve elderly acute myeloid leukemia (AML), and relapsed/refractory AML participants to receive the BED or MTD dose. Relapsed/refractory AML participants may also receive SGI-110 on a daily x 10 schedule based on the total dose per cycle evaluated in the Dose-escalation Segment using the 5-daily regimen.
- Being tested
- Guadecitabine
- Keywords
- SGI-110, DNA Hypomethylating Agent, Intermediate 1, Intermediate 2, CMML or High Risk MDS, AML
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GuadecitabineDrug
Also called SGI-110
Subcutaneous injection
| Study group | Role | What they receive |
|---|---|---|
| Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Experimental | Participants received starting dose of guadecitabine 3 milligrams per meter square (mg/m^2), subcutaneously (SC), daily from Days 1-5, of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression. Receives: Drug: Guadecitabine |
| Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Experimental | Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15, of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression. Receives: Drug: Guadecitabine |
| Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Experimental | Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18, of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression. Receives: Drug: Guadecitabine |
| Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with diagnosis relapsed/refractory (r/r) AML. Receives: Drug: Guadecitabine |
| Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r AML. Receives: Drug: Guadecitabine |
| Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Experimental | Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of r/r AML. Receives: Drug: Guadecitabine |
| Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of treatment naïve (TN) AML. Receives: Drug: Guadecitabine |
| Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of TN AML. Receives: Drug: Guadecitabine |
| Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Experimental | Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of TN AML. Receives: Drug: Guadecitabine |
| Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r Myelodysplastic Syndromes (MDS). Receives: Drug: Guadecitabine |
| Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r MDS. Receives: Drug: Guadecitabine |
| Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS. Receives: Drug: Guadecitabine |
| Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Participants received guadecitabine 90 mg/m^2, SC daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS. Receives: Drug: Guadecitabine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Measured: Cycle 1 Day 8
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Measured: Cycle 1 Day 15
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Measured: Cycle 1 Day 22
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Measured: Cycle 2 Day 1
Dose Escalation Phase-Maximum Tolerated Dose (MTD): Number of Participants With Dose Limiting Toxicity (DLT)
The MTD was defined as the largest dose for which less than 33% of subjects experienced a dose limiting toxicity (DLT) during Cycle 1 of guadecitabine administration at each dose level. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
Measured: From the start of study treatment up to 30 days post treatment (Up to approximately 46 months)
Dose Expansion (DE) Phase- r/r AML, TN AML: Composite Complete Response (CRc) Rate
Composite complete response (CRc) rate is defined as the percentage of participants whose best response is complete remission [CR], CR with incomplete platelet recovery [CRp], or CR with incomplete hematological recovery [CRi]) after treatment with study drug. CR as per AML response criteria is defined as peripheral blood absolute neutrophil count (ANC) ≥1.0×10^9/L, Platelets ≥100×10^9/L, independence from red blood cell (RBC) and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow.
Measured: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Expansion (DE) Phase- r/r MDS, TN MDS: Overall Response Rate (ORR)
ORR is defined as percentage of participants with complete response(CR), partial response(PR), marrow complete response(mCR) and haematological improvement(HI). CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or red blood cells transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L and by at least 100%,/if more than 20×10^9/L, by an absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, and by an absolute increase ≥0.5×10^9/L.
Measured: At end of each Cycle of 28 days (Up to approximately 45 months)
Secondary outcomes (20)
Dose Escalation Phase: Response Rate in AML Participants
Response rate for AML participants was assessed by Modified International Working Group (IWG) 2003 response criteria with complete response (CR), complete response with incomplete platelet recovery (CRp), CR with incomplete blood count recovery(CRi), and partial response (PR). CR: absolute neutrophil count (ANC) >1.0×10^9/L, platelets ≥100×10^9/L, independence from RBC and platelet transfusions, no or <5% myeloblasts in bone marrow(BM). CRp: ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions, no or <5% myeloblasts in BM. CRi: ANC <1.0×10^9/L, no or <5% myeloblasts in BM. PR: ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no or decrease of ≥50% in myeloblasts to 5-25% in BM.
Measured: At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation Phase: Response Rate in MDS Participants
Response rate for MDS participants was assessed by IWG 2006 Response Criteria with CR, PR, marrow complete response(mCR) and HI. CR: normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L; normal BM with persistent marrow blasts ≤5%; persistent dysplasia. PR: Normal peripheral counts with granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal BM with blasts >5% but reduced by 50% or more. mCR: reduction of BM blasts to ≤5% without normalization of peripheral counts.
Measured: At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation and Dose Expansion Phase- r/r AML, TN AML: Duration of Response
Duration of response (in number of days) was calculated from the first time a complete response (CR, CRp, or CRi) was observed to time of relapse defined as the earliest time point whereby BM blasts or peripheral blood blasts become ≥5% and stayed at that level in subsequent visits while participants were still on study. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow.
Measured: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation Phase: Hematologic Improvement Rate in MDS
Measured: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Duration of Response
DOR was calculated from first time a response category (CR, PR, mCR, or HI) was achieved until response category was no longer met or the last available time point, whichever occurred first. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L by at least 100%,/if more than 20×10^9/L, by absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10^9/L.
Measured: At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation r/r AML, TN AML: Time to Response
Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (cycle 1 day 1 {C1D1}) to the first day of response. Composite complete response rate (CRc = CR + CRp + CRi), which is an overall complete response assessment including CR, CR with incomplete platelet recovery (CRp) and CR with incomplete blood count recovery (CRi). CRc rate, was defined as the number of participants who achieved a response status of CR, CRp, or CRi divided by the total number of participants included in the efficacy dataset. The CR rate is defined as the number of participants whose best response is CR divided by the total number of participants included in the efficacy dataset.
Measured: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Expansion Phase- r/r MDS, TN MDS: Time to Response
Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (C1D1) to the first day of response. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L by at least 100%,/if more than 20×10^9/L, by absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10^9/L.
Measured: At end of each Cycle of 28 days (Up to approximately 45 months)
Number of Participants With Dose Limiting Toxicities (DLT) Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
DLT was defined using CTCAE v4.0. Toxicities were considered related to SGI-110 if it cannot be explained by underlying disease, intercurrent illness or concomitant medications. Any related Grade 3 or 4 non-hematologic toxicity except Grade 3 or 4 nausea/vomiting that is controllable by anti-emetics or diarrhea controllable by optimal therapy. Grade 3 laboratory investigations other than serum creatinine, bilirubin, AST or ALT were not considered a DLT unless they are associated with clinical manifestations. Study-drug related Grade 4 thrombocytopenia and Febrile neutropenia that was not present at study entry, and not resolve within 7 days, and is not related to underlying disease. Prolonged myelosuppression or pancytopenia with hypocellular bone marrow and no marrow blasts lasting for 6 weeks or more that is not related to disease progression. Any toxicity that results in treatment delays of > 4 weeks. Data is reported for any AE occurring during Cycle 1 (each cycle = 28 days).
Measured: Cycle 1 (each cycle = 28 days)
Dose Escalation and Dose Expansion Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With At Least One Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent AEs are defined as events that first occurred or worsened after the first dose of study drug given on C1D1 until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML, whichever occurs first, with the following exceptions: events that occurred after 30 days beyond the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML was considered treatment-emergent if the events are both serious and related to the study treatment.
Measured: From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With Abnormal Laboratory Values Reported as Adverse Events
Measured: From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation: Maximum Observed Plasma Concentration (Cmax ) of SGI-110 and Decitabine
Measured: Days 1, 5 and 8
Dose Escalation: Minimum Observed Plasma Concentration (Cmin)
Measured: Days 5 and 8
Dose Escalation: Area Under the Curve to Infinity (AUC0-inf)
Measured: Days 1, 5 and 8
Dose Escalation and DE Phase- r/r MDS, TN MDS: Time to AML or Death
Time to AML or death was defined as the number of days from the date the subject received the first dose of guadecitabine (C1D1) to the date of death or the date of MDS/ chronic myelomonocytic leukemia (CMML) progression to AML, whichever occurred earlier. Time to AML or death was evaluated using the Kaplan-Meier method, with the time censored on the last date of contact if a participant was still alive without progression to AML.
Measured: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Overall Survival
OS was defined as the number of days from the day the participant received the first dose of guadecitabine to the date of death (regardless of cause).
Measured: At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation: Number of Participants Achieving Blood and Platelet Transfusions
Measured: Cycle 1, Day 1 through 30 days after the last dose of study drug (up to approximately 46 months)
DE Phase- r/r AML, TN AML: Percentage of Participants With Cr, CRp and PR
CR is defined absolute neutrophil count (ANC) >1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp is defined ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi is defined as ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow. PR is defined as ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
Measured: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Percentage of Participants With CR, PR, mCR and HI
CR is defined ANC >1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp is defined ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi is defined as ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow. PR is defined as ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
Measured: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Blood Transfusion Independence for 8 or 16-weeks
Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Measured: Weeks 8 and 16
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Platelet Transfusion Independence for 8 or 16-weeks
Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Measured: Weeks 8 and 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2010 (estimated)
- Study start4 Jan 2011
- Primary completion22 Jul 2016
- Study completion22 Jul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for MDSStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 414 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01261312
- Sponsor's protocol ID
- SGI-110-01
- Status last verified
- Dec 2024
- First submitted
- 29 Nov 2010
- Last updated
- 23 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, Roboz GJ, Kantarjian HM, Azab M, Issa JJ. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin Epigenetics. 2019 Jul 22;11(1):106. doi: 10.1186/s13148-019-0704-3.
PubMed 31331399Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.
PubMed 31060979Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19.
PubMed 26296954
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
- ClinicalTrials.gov ID
- NCT01261312
- Acronym / sponsor ID
- SGI-110-01
- Keywords
- SGI-110, DNA Hypomethylating Agent, Intermediate 1, Intermediate 2, CMML or High Risk MDS, AML
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 414 participants (actual)
- Lead sponsor
- Astex Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 4 Jan 2011 (actual)
- Primary completion
- 22 Jul 2016 (actual)
- Study completion
- 22 Jul 2016 (actual)
- First posted
- 16 Dec 2010 (estimated)
- Results
- Posted 23 Jan 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML participants while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD) as defined in the Dose Escalation Segment.
Detailed description
Once the biologically effective dose (BED) and maximum tolerated dose (MTD) is determined in the Dose Escalation Segment, the Dose Expansion Segment will randomize participants with MDS, treatment naïve elderly acute myeloid leukemia (AML), and relapsed/refractory AML participants to receive the BED or MTD dose. Relapsed/refractory AML participants may also receive SGI-110 on a daily x 10 schedule based on the total dose per cycle evaluated in the Dose-escalation Segment using the 5-daily regimen.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 13
| Arm | Type | Receives |
|---|---|---|
| Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily | Experimental | Drug: GuadecitabineParticipants received starting dose of guadecitabine 3 milligrams per meter square (mg/m^2), subcutaneously (SC), daily from Days 1-5, of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression. |
| Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly | Experimental | Drug: GuadecitabineParticipants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15, of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression. |
| Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly | Experimental | Drug: GuadecitabineParticipants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18, of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression. |
| Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with diagnosis relapsed/refractory (r/r) AML. |
| Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r AML. |
| Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of r/r AML. |
| Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of treatment naïve (TN) AML. |
| Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of TN AML. |
| Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of TN AML. |
| Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r Myelodysplastic Syndromes (MDS). |
| Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r MDS. |
| Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS. |
| Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) | Experimental | Drug: GuadecitabineParticipants received guadecitabine 90 mg/m^2, SC daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Men or women, 18 years of age or older, with a confirmed diagnosis of international prognostic scoring system (IPSS) intermediate-1, intermediate-2 or high-risk MDS including Chronic Myelomonocytic Leukemia (CMML) or AML.
- Eastern ECOG performance status of 0 to 2.
- Adequate organ function.
- Prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be ≥ 2 weeks off immunosuppressive therapy.
- No major surgery within 4 weeks of first dose of SGI-110.
Key exclusion criteria (7 listed)
- In the Dose Expansion Segment, which includes the 10-day regimen, participants who have received 2 complete full dose cycles or more of a hypomethylating agent (HMA) decitabine or azacitidine (except for intermediate-2 or high-risk MDS participant (including CMML) relapsed or refractory to prior HMA treatment).
- Acute promyelocytic leukemia (M3 classification).
- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the participant has been disease free for at least 3 years.
- Life-threatening illnesses other than AML or MDS, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the participant's safety, or put the study outcomes at risk.
- Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GuadecitabineAlso: SGI-110Subcutaneous injection | Drug | Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily, Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly, Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly, Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day), Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day), Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day), Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day), Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day), Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day), Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day), Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day), Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day), Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) |
Primary outcome
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
Time frame: Cycle 1 Day 8
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
Time frame: Cycle 1 Day 15
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
Time frame: Cycle 1 Day 22
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation
Time frame: Cycle 2 Day 1
DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Dose Escalation Phase-Maximum Tolerated Dose (MTD): Number of Participants With Dose Limiting Toxicity (DLT)
Time frame: From the start of study treatment up to 30 days post treatment (Up to approximately 46 months)
The MTD was defined as the largest dose for which less than 33% of subjects experienced a dose limiting toxicity (DLT) during Cycle 1 of guadecitabine administration at each dose level. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
Dose Expansion (DE) Phase- r/r AML, TN AML: Composite Complete Response (CRc) Rate
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Composite complete response (CRc) rate is defined as the percentage of participants whose best response is complete remission [CR], CR with incomplete platelet recovery [CRp], or CR with incomplete hematological recovery [CRi]) after treatment with study drug. CR as per AML response criteria is defined as peripheral blood absolute neutrophil count (ANC) ≥1.0×10^9/L, Platelets ≥100×10^9/L, independence from red blood cell (RBC) and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow.
Dose Expansion (DE) Phase- r/r MDS, TN MDS: Overall Response Rate (ORR)
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
ORR is defined as percentage of participants with complete response(CR), partial response(PR), marrow complete response(mCR) and haematological improvement(HI). CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or red blood cells transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L and by at least 100%,/if more than 20×10^9/L, by an absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, and by an absolute increase ≥0.5×10^9/L.
20 secondary outcomes
Dose Escalation Phase: Response Rate in AML Participants
Time frame: At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation Phase: Response Rate in MDS Participants
Time frame: At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation and Dose Expansion Phase- r/r AML, TN AML: Duration of Response
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation Phase: Hematologic Improvement Rate in MDS
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Duration of Response
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation r/r AML, TN AML: Time to Response
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Expansion Phase- r/r MDS, TN MDS: Time to Response
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
Number of Participants With Dose Limiting Toxicities (DLT) Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Time frame: Cycle 1 (each cycle = 28 days)
Dose Escalation and Dose Expansion Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With At Least One Treatment-Emergent Adverse Events (TEAEs)
Time frame: From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With Abnormal Laboratory Values Reported as Adverse Events
Time frame: From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation: Maximum Observed Plasma Concentration (Cmax ) of SGI-110 and Decitabine
Time frame: Days 1, 5 and 8
Dose Escalation: Minimum Observed Plasma Concentration (Cmin)
Time frame: Days 5 and 8
Dose Escalation: Area Under the Curve to Infinity (AUC0-inf)
Time frame: Days 1, 5 and 8
Dose Escalation and DE Phase- r/r MDS, TN MDS: Time to AML or Death
Time frame: At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Overall Survival
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation: Number of Participants Achieving Blood and Platelet Transfusions
Time frame: Cycle 1, Day 1 through 30 days after the last dose of study drug (up to approximately 46 months)
DE Phase- r/r AML, TN AML: Percentage of Participants With Cr, CRp and PR
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Percentage of Participants With CR, PR, mCR and HI
Time frame: At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Blood Transfusion Independence for 8 or 16-weeks
Time frame: Weeks 8 and 16
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Platelet Transfusion Independence for 8 or 16-weeks
Time frame: Weeks 8 and 16
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 31331399Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, Roboz GJ, Kantarjian HM, Azab M, Issa JJ. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin Epigenetics. 2019 Jul 22;11(1):106. doi: 10.1186/s13148-019-0704-3.
- Derived from this study: PubMed 31060979Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.
- Derived from this study: PubMed 26296954Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19.
Related trials for MDS
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 1/2
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
High Grade Myelodysplastic Syndromes
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 1
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
16 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Guadecitabine in people with MDS and CMML, run by Astex Pharmaceuticals, Inc. at 16 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation (time frame: Cycle 1 Day 8). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01261312, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2025.